RU2015119640A - Соединения n-замещенного индазол-сульфонамида с избирательной активностью в потенциал-зависимых натриевых каналах - Google Patents

Соединения n-замещенного индазол-сульфонамида с избирательной активностью в потенциал-зависимых натриевых каналах Download PDF

Info

Publication number
RU2015119640A
RU2015119640A RU2015119640A RU2015119640A RU2015119640A RU 2015119640 A RU2015119640 A RU 2015119640A RU 2015119640 A RU2015119640 A RU 2015119640A RU 2015119640 A RU2015119640 A RU 2015119640A RU 2015119640 A RU2015119640 A RU 2015119640A
Authority
RU
Russia
Prior art keywords
sulfonamide
indazole
fluoro
alkyl
ethyl
Prior art date
Application number
RU2015119640A
Other languages
English (en)
Russian (ru)
Inventor
Джозеф Е. ПЕРО
Ханна Д. Дж. Ф. ЛЕМАН
Марк Э. Лейтон
Майкл А. Росси
Майкл Дж. Келли III
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Publication of RU2015119640A publication Critical patent/RU2015119640A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2015119640A 2012-10-26 2013-10-23 Соединения n-замещенного индазол-сульфонамида с избирательной активностью в потенциал-зависимых натриевых каналах RU2015119640A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719118P 2012-10-26 2012-10-26
US61/719,118 2012-10-26
PCT/US2013/066360 WO2014066491A1 (en) 2012-10-26 2013-10-23 N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels

Publications (1)

Publication Number Publication Date
RU2015119640A true RU2015119640A (ru) 2016-12-20

Family

ID=50545213

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015119640A RU2015119640A (ru) 2012-10-26 2013-10-23 Соединения n-замещенного индазол-сульфонамида с избирательной активностью в потенциал-зависимых натриевых каналах

Country Status (10)

Country Link
US (1) US9388179B2 (US07794700-20100914-C00152.png)
EP (1) EP2911663B1 (US07794700-20100914-C00152.png)
JP (1) JP2015535252A (US07794700-20100914-C00152.png)
KR (1) KR20150074123A (US07794700-20100914-C00152.png)
CN (1) CN104869992A (US07794700-20100914-C00152.png)
AU (1) AU2013334664A1 (US07794700-20100914-C00152.png)
BR (1) BR112015008987A2 (US07794700-20100914-C00152.png)
CA (1) CA2891056A1 (US07794700-20100914-C00152.png)
RU (1) RU2015119640A (US07794700-20100914-C00152.png)
WO (1) WO2014066491A1 (US07794700-20100914-C00152.png)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US8952169B2 (en) 2012-05-22 2015-02-10 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
EP2870138B1 (en) 2012-07-06 2018-08-22 Genentech, Inc. N-substituted benzamides and methods of use thereof
CA2898679A1 (en) 2013-03-14 2014-09-25 Xenon Pharmaceuticals Inc. Substituted triazolopyridines and methods of use thereof
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
US9783527B2 (en) * 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
JP2018507900A (ja) * 2015-03-13 2018-03-22 アッヴィ・インコーポレイテッド (インダゾール−4−イル)ヘキサヒドロピロロピロロン及び使用方法
MX2017014715A (es) 2015-05-22 2018-03-16 Genentech Inc Benzamidas sustituidas y metodos para utilizarlas.
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3356360A1 (en) 2015-09-28 2018-08-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
TW201726637A (zh) 2015-12-18 2017-08-01 默沙東藥廠 對電位閘控鈉通道具選擇活性之羥基烷基胺-及羥基環烷基胺-取代之二胺-芳基磺胺化合物
CN109071426A (zh) 2016-03-30 2018-12-21 基因泰克公司 取代的苯甲酰胺及其使用方法
JP6938545B2 (ja) 2016-05-20 2021-09-22 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
RU2019114964A (ru) 2016-10-17 2020-11-17 Дженентек, Инк. Терапевтические средства и способы их применения
KR20190086772A (ko) 2016-12-09 2019-07-23 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック, インコーポレイテッド ナトリウムチャネル阻害剤としての4−ピペリジン−n−(ピリミジン−4−イル)クロマン−7−スルホンアミド誘導体
CN107247885B (zh) * 2017-07-06 2020-07-03 中国水产科学研究院黄海水产研究所 一种电压-门控钠离子通道的结构预测方法
US11028075B2 (en) 2018-02-26 2021-06-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
WO2019241533A1 (en) 2018-06-13 2019-12-19 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US10752623B2 (en) 2018-08-31 2020-08-25 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
EP3844150A1 (en) 2018-08-31 2021-07-07 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
WO2020192553A1 (zh) * 2019-03-22 2020-10-01 上海海雁医药科技有限公司 磺酰基取代的苯并杂环甲酰胺衍生物、其制法与医药上的用途
WO2023186058A1 (zh) * 2022-03-31 2023-10-05 江苏恒瑞医药股份有限公司 吲唑类化合物、其制备方法及其在医药上的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705185A (en) 1969-04-14 1972-12-05 Minnesota Mining & Mfg N-aroyl sulfonamides
US4242273A (en) 1977-09-27 1980-12-30 American Cyanamid Company 4-(Monoalkylamino)benzoic acid amides and imidates
US4309553A (en) 1977-09-27 1982-01-05 American Cyanamid Company Aldehydes and ketones containing a 4-(monoalkylamino)-benzoyl substituent
US4136256A (en) 1977-09-27 1979-01-23 American Cyanamid Company 4-(monoalkylamino)benzoic acid imidates
US4254138A (en) 1977-12-19 1981-03-03 American Cyanamid Company Esters of 4-(monoalkylamino)benzoic hydroxyalkanoic acids
US4272546A (en) 1977-12-19 1981-06-09 American Cyanamid Company Esters of 4-(monoalkylamino)benzoic hydroxyalkanoic acids
US4230628A (en) 1978-04-12 1980-10-28 American Cyanamid Company 4-[(Carboxyl- and sulfamyl-substituted alkyl)-amino] benzoic acids and analogs
US4211783A (en) 1978-03-20 1980-07-08 American Cyanamid Company Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds
US4243609A (en) 1978-02-02 1981-01-06 American Cyanamid Company Ring-fluorinated 4-(hexadecyl-amino) N-substituted benzamide compounds
US4227014A (en) 1978-02-27 1980-10-07 American Cyanamid Company 4-[(Cycloalkyl or cycloalkenyl substituted)amino, alkylamino or alkenylamino]benzoic acids and salts thereof
US4205085A (en) 1978-03-09 1980-05-27 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds
US4245097A (en) 1978-02-27 1981-01-13 American Cyanamid Company 4-[(Monosubstituted-alkyl) amino] benzoic acids and analogs as hypolipidemic and antiatherosclerotic agents
US4230878A (en) 1978-03-08 1980-10-28 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-[(cyclopropyl alkyl)amino]benzoic acids and derivatives
US4305959A (en) 1978-03-09 1981-12-15 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds
US4318914A (en) 1978-03-09 1982-03-09 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds
US4310545A (en) 1978-03-09 1982-01-12 American Cyanamid Company Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds
US4485105A (en) 1978-10-12 1984-11-27 American Cyanamid Company Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides
DK471479A (da) 1978-12-13 1980-06-14 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
US4670421A (en) 1982-07-12 1987-06-02 American Cyanamid Company Antiatherosclerotic silanes
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
SE0402762D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
RU2007145434A (ru) * 2005-05-10 2009-06-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов ионных каналов
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
JP2012506857A (ja) * 2008-10-23 2012-03-22 メルク・シャープ・エンド・ドーム・コーポレイション 縮合複素環式m1受容体ポジティブアロステリック調節因子
MX2011007424A (es) 2009-01-12 2011-08-12 Icagen Inc Derivados de sulfonamida.
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
CA2804593C (en) * 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
EP2590957B1 (en) 2010-07-09 2014-11-12 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
CA2800971A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
WO2012064984A1 (en) 2010-11-10 2012-05-18 Datalogic Scanning, Inc. Adaptive data reader and method of operating
WO2012095781A1 (en) * 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
JP2014521749A (ja) 2011-08-17 2014-08-28 アムジエン・インコーポレーテツド ヘテロアリールナトリウムチャネル阻害剤
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
US9012443B2 (en) 2011-12-07 2015-04-21 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors

Also Published As

Publication number Publication date
EP2911663A1 (en) 2015-09-02
EP2911663B1 (en) 2020-03-18
US9388179B2 (en) 2016-07-12
AU2013334664A1 (en) 2015-05-07
CA2891056A1 (en) 2014-05-01
KR20150074123A (ko) 2015-07-01
WO2014066491A1 (en) 2014-05-01
US20150284389A1 (en) 2015-10-08
CN104869992A (zh) 2015-08-26
JP2015535252A (ja) 2015-12-10
BR112015008987A2 (pt) 2017-07-04
EP2911663A4 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
RU2015119640A (ru) Соединения n-замещенного индазол-сульфонамида с избирательной активностью в потенциал-зависимых натриевых каналах
JP2015535252A5 (US07794700-20100914-C00152.png)
ES2535290T3 (es) Compuestos de isoindolina sustituidos en posición 5
JP2023144075A (ja) 癌治療用ptpn11(shp2)阻害剤としての6-(4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル)-3-(2,3-ジクロロフェニル)-2-メチルピリミジン-4(3h)-オン誘導体及び関連化合物
CA2904794C (en) Modulators of the eif2alpha pathway
ES2434946T3 (es) Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
ES2426350T3 (es) Compuestos de isoindolina sustituidos en 5
JP5637852B2 (ja) 6、7又は8置換キナゾリノン誘導体並びにそれらを含有する組成物及びそれらを使用する方法
CN108484571B (zh) 化合物的盐和固体形式,包含其的组合物及其使用方法
ES2634915T3 (es) Derivados de quinazolinona 5-sustituidos como agentes anti-cancerosos
KR101791757B1 (ko) 4'-o-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
AU2009311477B2 (en) Isoindoline compounds for use in the treatment of cancer
AU2018360850A1 (en) Modulators of the integrated stress pathway
CA3080808A1 (en) Modulators of the integrated stress pathway
CN116283647A (zh) 整合应激通路的前药调节剂
PE20110684A1 (es) Agonistas de los receptores de la melanocortina
PH12014501626B1 (en) Therapeutically active compounds and their methods of use
CA2982890A1 (en) Plk4 inhibitors
WO2009042200A1 (en) Solid forms comprising 3-(2,5-dimethyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same
WO2023069514A2 (en) Bifunctional compounds for degrading itk via ubiquitin proteosome pathway

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180201